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Abstract: The convenient synthesis of a library of novel 6,6,5-tricyclic thiazolo[5,4-f] 
quinazolines (forty molecules) was achieved mainly under microwave irradiation. Dimroth 
rearrangement and 4,5-dichloro-1,2,3,-dithiazolium chloride (Appel salt) chemistry were 
associated for the synthesis of a novel 6-aminobenzo[d]thiazole-2,7-dicarbonitrile (16) a 
versatile molecular platform for the synthesis of various bioactive derivatives. Kinase 
inhibition of the final compounds was evaluated on a panel of four Ser/Thr kinases 
(DYRK1A, CDK5, CK1 and GSK3) chosen for their strong implications in various 
regulation processes, especially Alzheimer’s disease (AD). In view of the results of this 
preliminary screening, thiazolo[5,4-f]quinazoline scaffolds constitutes a promising source of 
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inspiration for the synthesis of novel bioactive molecules. Among the compounds of  
this novel chemolibrary, 7i, 8i and 9i inhibited DYRK1A with IC50 values ranging in the 
double-digit nanomolar range (40, 47 and 50 nM, respectively). 
Keywords: thiazolo[5,4-f]quinazolines; kinases inhibitors; DYRK1A; GSK3α/β; 
microwave-assisted chemistry; Dimroth rearrangement; appel salt 
 
1. Introduction 
Kinases are one of the largest enzyme families of the genome. More than 500 kinases play an 
important role in the regulation of most cellular processes. These enzymes are involved in all major 
diseases, including cancer, neurodegenerative disorders and cardiovascular diseases [1–3]. Our research 
groups are mainly invested in the synthesis of C,N,S- or C,N,O-containing heterocyclic precursors of 
bioactive molecules able to modulate the activity of kinases in signal transduction [4–8]. 
In the course of our work based on microwave-assisted chemistry, we described ten years ago the 
multistep synthesis of the 8H-thiazolo[5,4-f]quinazolin-9-ones (A) [9,10]. Brief studies of their 
structure-activity relationships as dual CDK1/GSK-3 kinases inhibitors were described [7]. At that time, 
the inhibitory potency of the final products was evaluated and some products showed a micromolar range 
affinity against DYRK1A [11]. More recently, the synthesis and the kinase inhibitory potency of various 
benzo-, pyrido- and pyrazinothieno[3,2-d]pyrimidines derivatives (B), have been published. Kinase 
inhibition of the compounds was evaluated on Ser/Thr kinases (CDK5, GSK3, DYRK1A, CLK1 and 
CK1) selected for their strong implications in various human pathologies, especially in AD [3].  
The overall pharmaceutical interest of all these compounds encouraged us to conceive new series of 
thiazolo[5,4-f]quinazolines substituted in position 4 of the pyrimidine ring by an aromatic amine and by 
carboximidamide groups in position 2 of the thiazole moiety (see general formula C in Scheme 1).  
Scheme 1. Structures of previous molecules which inspired the current work. 
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These compounds were conceived as 6,6,5-tricyclic homologues of the basic 4-aminoquinazoline 
pharmacophore which is present in approximately 80% of ATP-competitive kinase inhibitors that have 
received approval for the treatment of cancer [11]. The aromatic amine groups linked to the main 
thiazoloquinazoline structure were selected because of their frequent presence in drugs or drug 
candidates [11]. On the other side of the target molecules, the aliphatic chains of the carboximidamide 
groups were also chosen because of their frequent presence in many drugs. 
This paper describes the development of a simple and reliable method that allows the preparation of 
a library of new thiazolo[5,4-f]quinazolines for which interesting kinase inhibitory activities were 
observed. The main part of the chemistry described in this paper was achieved under microwave 
irradiation as a continuation of our global strategy which consists to design adapted reactants and 
techniques offering operational, economic, and environmental benefits over conventional methods [12]. 
2. Results and Discussion 
2.1. Synthesis 
The target molecules we studied were thiazolo[5,4-f]quinazolines (C) substituted in position 4 of the 
pyrimidine ring (which corresponds to position 9 of the tricyclic compound) by an aromatic amine. The 
retrosynthetic pathway depicted in Scheme 2 was directly inspired by our previous work on the synthesis 
of various thiazoloquinazoline isomers [13,14] and on general access to pyrimidine-condensed 
heterocyclic compounds [15]. It suggested introducing the thiazole ring via a copper(I)-mediated 
cyclization of ortho-brominated N-arylimino-1,2,3-dithiazoles intermediates. The latter would be isolated 
after condensation of 4,5-dichloro-1,2,3-dithiazolium chloride (Appel salt) [16] with a key N2-protected 
brominated aminoanthranilonitrile. The synthesis of the final pyrimidinic structures was envisioned via 
a microwave-assisted thermal-sensitive Dimroth rearrangement. [17] A nucleophilic attack of intermediate 
amidines by various aromatic amines would give the expected tricyclic compounds. This fast and convenient 
procedure was recently explored for the design of novel bioactive 4-anilinoquinazolines [4,5,17].  
Scheme 2. General retrosynthetic pathways envisioned for this work. 
 
The synthetic route described in Scheme 2 was applied to the preparation of some of our target 
molecules. It started from 2-amino-5-nitroanthranilonitrile (1) which was treated for 15 min at 105 °C 
with N,N-dimethylformamide dimethyl acetal (DMFDMA) under microwave irradiation. The resulting 
N,N-dimethylformamidine 2 was heated with the appropriate aromatic amine in the presence of acetic 
acid at 118 °C for 20 min. Compounds 3a–d were then obtained in two steps in a good average yield  
of 85%. 
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In order to isolate the desired aryliminodithiazoles, 4-substituted-6-nitroquinazolinones 3a–c were 
first reduced into 6-amino derivatives 4a–c by transfer hydrogenation using ammonium formate in 
refluxing ethanol. Expectedly, in these conditions, the palladium-catalyzed reduction of the nitro  
group of intermediate 3d also provoked the protodehalogenation of the chloride atom of the  
3-chloro-4-fluoroaniline moiety. This difficulty was circumvented when the reduction of 3d was 
achieved with iron and acetic acid in refluxing ethanol to give 4d in excellent yield (99%). 
Compounds 4a–d were treated with bromine in acetic acid to yield the ortho brominated imines 5a–d. 
In the case of 4b, a polybrominated by-product 5e was obtained along with 5b whatever the conditions 
tested. Unfortunately both derivatives 5b and 5e were inseparable under convenient conditions. Another 
route consisting in preliminary bromination of the starting 5-nitroanthranilonitrile (1) was experimented. 
Unfortunately, whatever the bromination method, only 3-bromo-5-nitroanthranilonitrile (1b) was 
detected (see alternative route in Scheme 3). 
Scheme 3. Synthetic routes experimented for the access to the target compounds (series 7–10). 
 
Reagents and conditions: (a) DMFDMA, DMF, 70 °C (μw), 2 min, 94%; (b) aniline (1.5 eq), AcOH, 118 °C 
(μw), 2 min, 99% (3a)/45 min, 95% (3b)/30 min, 70% (3c)/10 min, 77% (3d); (c) HCO2NH4, Pd.C, EtOH, 
78 °C (μw), 30 min, 99% (4a)/, 99% (4b)/93% (4c) or Fe, AcOH, EtOH, 78 °C (μw), 5 h, 99% (4d); (d) Br2, 
AcOH, CH2Cl2, r.t., 3.5 h; quant.; (e) Appel salt, Py. (2 eq), CH2Cl2, r.t., 4 h, 39% (6a)/30% (6c)/39% (6d);  
(f) CuI, Py., 130 °C (μw), 20 min, 24% (7)/49% (8)/30% (9)/64% (10).  
Brominated intermediates 5a, 5c and 5d were condensed with 4,5-dichloro-1,2,3-dithiazolium 
chloride (Appel salt) in dichloromethane at room temperature and subsequent addition of pyridine led to 
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the desired ortho-halogenated N-aryliminodithiazoles 6a, 6c and 6d. The latter were converted into 
thiazolo[5,4-f]quinazoline-2-carbonitriles 7, 9 and 10 in copper(I)-catalyzed conditions [14,16]. 
Despite its effectiveness, this synthesis presents some limitations. Each modification of the substituent 
in N3 of the pyrimidine ring (e.g., 3a–d) generates three intermediates (e.g., 4a–d, 5a, c and d and 6a–d in 
this study) for which synthetic and biological significance are not really established yet. The second 
drawback of this synthetic route lies in the reduction and bromination steps both of which require being 
adapted to the aromatic substituent of the intracyclic N3-nitrogen atom. As an example, compound 5b 
was never isolated in analytically pure form and the synthesis of 8 via this intermediate was judged infeasible. 
In order to avoid the limitations inherent in the first synthetic route and acquire an efficient and 
versatile route to various 9-anilinothiazolo[5,4-f]quinazolines, a rational multistep synthesis of a novel 
polyfunctionalized benzothiazole (see 16 in Scheme 4) was accomplished. This molecular system was 
designed as an efficient precursor of various target molecules.  
Scheme 4. Multistep synthesis of polyfunctionalized benzothiazole 16. 
 
Reagents and conditions: (a) Boc2O, DMAP, Et3N, CH2Cl2, r.t., 4 h; (b), HCO2NH4, Pd.C, EtOH, 78 °C (μw),  
30 min; (c) Br2, AcOH, CH2Cl2, r.t., 2.5 h; (d) Appel salt, Py. (2 eq), CH2Cl2, r.t., 4 h; (e) AcOH, 118 °C (μw), 
2 h; (f) CuI, Py., 130 °C (μw), 20 min. 
Protection of 2-amino-5-nitrobenzonitrile (1) using di-tert-butyl dicarbonate was performed at room 
temperature in dichloromethane in the presence of triethylamine and 4-(dimethylamino)pyridine and 
provided tert-butyl (2-cyano-4-nitrophenyl)carbamate (11) in 91% yield. Reduction of the nitro group 
of 11 was carried out as previously shown by palladium-catalyzed transfer hydrogenation in refluxing 
ethanol under microwave irradiation for 30 min and gave tert-butyl 4-amino-2-cyanophenylcarbamate 
12 in high yield. Treatment of intermediate 12 with a solution of bromine in dichloromethane in acetic 
acid at room temperature provided tert-butyl 4-amino-3-bromo-2-cyanophenylcarbamate 13 in 
quantitative yield. The latter was reacted with Appel salt (4,5-dichloro-1,2,3-dithiazolium chloride) in 
dichloromethane at room temperature to afford tert-butyl-3-bromo-4-(4-chloro-5H-1,2,3-dithiazol-5-
ylideneamino)-2-cyanophenylcarbamate (14). N-Boc deprotection of 14 by acetic acid under microwave 
irradiation at 118 °C gave 6-amino-2-bromo-3-(4-chloro-5H-1,2,3-dithiazol-5-ylidene-amino)benzonitrile 
15 in quantitative yield. Finally a copper-mediated cyclization of 15 was accomplished with CuI in 
pyridine under microwave irradiation at 130 °C for 20 min to give 6-aminobenzo[d]thiazole-2,7-
dicarbonitrile 16 in good yield (67%).  
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On a practical aspect, this synthetic sequence is easily upscalable and 10 g of 2-amino-5-nitro-
benzonitrile (1) led to 2 g of 16 in an average 23% yield. This new compound 16 can be considered as a 
molecular platform that can be employed in new areas of investigation and prove its utility for the 
synthesis of innovative molecular systems with potent biological applications. Indeed, the versatile 
carbonitrile function in position 2 of the thiazole ring may allow the synthesis of various amidine, 
imidazoline and imidate derivatives. On the other side the 2-aminobenzonitrile moiety offers a large 
panel of possibilities for extension of the aromatic structure with a heterocyclic core such as a pyrimidine 
(Scheme 5). 
Scheme 5. Possible transformations of benzothiazole 16 as a versatile molecular platform. 
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The synthesis of the target molecules was carried on by treatment of 16 with DMFDMA  
under microwave irradiation at 70 °C to give (E)-N'-(2,7-dicyanobenzo[d]thiazol-6-yl)-N,N-
dimethylformimidamide (17) in good yield (86%). Cyclization of formimidamide 17 into thiazolo[5,4-
f]quinazoline-2-carbonitriles was accomplished via thermal Dimroth rearrangement using 1.5 eq of the 
appropriate aniline in acetic acid under microwave irradiation at 118 °C for short times and gave 
compounds 7–10 in good yields (71%–85%). This method constitutes a versatile route to various 
compounds, especially 8 which was obtained in excellent yield (98%). 
In order to enhance the chemodiversity of the thiazolo[5,4-f]quinazolines studied, the reactivity of the 
aromatic carbonitriles 7–10 was tested against a panel of substituted amines (mainly alkylamines) 
inspired by our previous studies [4,5]. A new set of 27 novel carboximidamides 7a–g, 8a–f, 9a–g and 
10a–g was prepared by stirring overnight at room temperature carbonitriles 7–10 with the appropriate 
amines (1.2 eq) in dry THF under argon. The chemical structures and yields obtained for the synthesis 
of the four prepared series (7a–g–10a–g) are shown in Table 1. 
The key molecules 7–10 were also heated with sodium hydroxide (2.5 N in water) or with a solution 
of sodium methoxide in methanol to give respectively amides 7h–10h and methyl imidates 7i–10i in 
good to excellent yields (Scheme 6). 
Note that microwave heating was mainly realized at atmospheric pressure in a controlled multimode 
cavity with a microwave power delivery system ranging from 0 to 1200 W. Concerning the technical 
aspect, the choice of a reactor able to work at atmospheric pressure was guided by our previous experience 
in microwave-assisted heterocyclic synthesis, especially in the chemistry of quinazolines [6,9]. Open 
vessel microwave experiments have some advantages, such as the possibility of easier scale-up and the 
possibility to use current laboratory glassware. Our choice was also guided by a recent work describing 
the tendency of pressure to accumulate when a product as DMFDMA was heated in pressurized vials, 
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especially under microwaves [18]. In most cases of our study, an irradiation of 800 W was enough  
to efficiently reach the programmed temperature. This parameter was mainly monitored via a 
contactless-infrared pyrometer which was calibrated in control experiments with a fiber-optic  
contact thermometer. 
Scheme 6. Synthesis of thiazolo[5,4-f]quinazoline-2-carbonitriles 7–10 and their derivatives 
via transformation of the carbonitrile functions in carboxamidines (a–g), amides (h) or 
imidates (i). 
 
Reagents and conditions: (a) DMFDMA, DMF, 70 °C (μw), 2 min, 86%; (b) aniline (1.5 eq), AcOH, 118 °C 
(μw), 2 min, 99% (7)/45 min, 95% (8)/30 min, 70% (9)/10 min, 77% (10); (c) amines, THF, r.t., 12 h, for yields 
see Table 1; (d) NaOHaq (2.5 N), butanol, 117 °C (μw), 30 min, 98% (7h)/91% (8h)/71% (9h)/98% (10h);  
(e) NaOMe (0.5 M in MeOH), MeOH, 65 °C (μw), 30 min, 82% (7i)/92% (8i)/94% (9i)/98% (10i). 
Table 1. Chemical structures and yields obtained for the synthesis of the four series (7a–g–10a–g). 
R1 R2 Compound Yield a (%) R1 R2 Compound Yield a (%) 
 
7a 41 
 
9a 85 
7b 43 
 
9b 72 
7c 47 
 
9c 68 
7d 53 9d 64 
7e 50 
 
9e 86 
7f 28 9f 68 
 7g 67 9g 40 
  
Molecules 2014, 19 15553 
 
 
Table 1. Cont. 
R1 R2 Compound Yield a (%) R1 R2 Compound Yield a (%) 
 
8a 41 
 
10a 71 
8b 34 
 
10b 82 
8c 48 
 
10c 69 
8d 30 10d 50 
8e 66 
 
10e 50 
8f 21 10f 69 
 8g -
b 10g 43 
a Isolated yield; b Not prepared. 
2.2. Biological Studies 
Compounds of series 7 (7, 7a–i), series 8 (8, 8a–i), series 9 (9, 9a–i) and series 10 (10, 10a–i)  
were tested on four different in vitro kinase assays (CDK5/p25 (cyclin-dependent kinase), CK1δ/ε 
(casein kinase 1), GSK3α/β(Glycogen Synthase Kinase 3) and DYRK1A (dual-specificity, tyrosine 
phosphorylation regulated kinase) to evaluate their inhibition potency [19–23]. These four kinases are 
all involved in Alzheimer’s disease (AD), a multi-kinase inhibitor able to target two or three of them 
could be quite desirable. This is linked to the fact that it is still not known whether any of these four 
kinases plays a more prominent role in Alzheimer’s disease than the others and, consequently, which 
one should therefore preferably be targeted. In pathological situations such kinases are overexpressed 
and-activated, this fact justify the interest of multi-target-directed ligands (MTDLs) while complete 
inhibition is likely to be detrimental.  
All compounds were first tested at a final concentration of 10 µM. Compounds showing less than 
50% inhibition were considered as inactive (IC50 > 10 µM). Compounds displaying more than 50% 
inhibition at 10 µM were next tested over a wide range of concentrations (usually from 0.01 to 10 µM), 
and IC50 values were determined from the dose-response curves (Sigma-Plot). Harmine is a β-carboline 
alkaloid known to be a potent inhibitor of DYRK1A [24]. Leucettine L41 is also a potent DYRK1A 
inhibitor derived from a marine natural product, Leucettamine B [25,26]. They were tested as positive 
controls and their IC50 values were compared with those obtained for the compounds under study. 
Results given in Table 2 demonstrate that none of the thiazolo[5,4-f]quinazoline derivatives exhibited 
any inhibitory activity against CDK5/p25 and CK1. Precursors 7, 8, 9 and 10, were completely inactive 
against all four tested kinases (IC50 > 10 μM). 
On a general aspect, compounds a–f of series 7, 9 and 10 were also judged inactive against DYRK1A, 
except for some compounds (8b–8e) of series 8 for which micromolar IC50 values were observed. Note 
that among the four families of tested molecules, all compounds of a–f series were found relatively 
active (mainly in the micromolar range) against GSK3α/β. All these compounds were substituted with 
bulky aminoethyl groups on the carboximidamide function of the final structures. The large size of these 
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groups appeared to influence the reactivity of the products against the four kinases tested, conferring 
them a relative selectivity for GSK3α/β (1.10 μM < IC50 < 7.00 μM). 
Table 2. Kinase inhibitory activity a,b,c of the four thiazolo[5,4-f]quinazoline series (7a–i–10a–i).  
Compound DYRK1A CK1 CDK5 GSK3 Compound DYRK1A CK1 CDK5 GSK3
7 >10 >10 >10 ≥10 9 >10 >10 >10 >10 
7a >10 >10 >10 1.10 9a >10 >10 >10 1.8 
7b >10 >10 >10 2.50 9b >10 >10 >10 0.53 
7c >10 >10 >10 2.00 9c >10 >10 >10 2.20 
7d >10 >10 >10 >10 9d >10 >10 >10 0.95 
7e 4.00 >10 >10 1.30 9e >10 >10 >10 2.10 
7f 8.00 >10 >10 2.00 9f >10 >10 >10 1.80 
7g 0.70 >10 >10 1.10 9g 0.27 >10 >10 0.60 
7h 0.50 >10 >10 0.30 9h 0.67 >10 >10 0.13 
7i 0.040 >10 >10 0.20 9i 0.050 >10 >10 0.16 
8 >10 >10 >10 ≥10 10 >10 >10 >10 >10 
8a 2.20 >10 >10 0.97 10a >10 >10 >10 3.50 
8b 2.00 >10 >10 1.10 10b >10 >10 >10 1.40 
8c 1.10 >10 >10 0.36 10c >10 >10 >10 2.50 
8d 1.05 >10 >10 0.25 10d >10 >10 >10 3.00 
8e 6.50 >10 >10 0.80 10e >10 >10 >10 7.00 
8f >10 >10 >10 2.00 10f >10 >10 >10 >10 
8g -d - - - 10g 6.50 >10 >10 7.20 
8h 0.80 >10 >10 0.77 10h 1.60 >10 >10 0.66 
8i 0.047 >10 >10 0.66 10i 0.25 >10 >10 0.69 
a IC50 values are reported in μM. The most significant results are presented in bold; b Kinases activities were 
assayed in triplicate. Typically, the standard deviation of single data points was below 10%; c Harmine (IC50 in μM): 
DYRK1A: 0.029; CK1: 1.50; CDK5 and GSK3α/β: > 10 [27]; Leucettine L41 (IC50 in μM): DYRK1A: 0.040; 
CK1: > 10; CDK5: > 10 and GSK3α/β: 0.040 [27]; d Not determined. 
Among the compounds tested, the two most interesting series are 8 and 9 which showed 
submicromolar values against GSK3 α/β. From this point of view, series 8 is really promising with 
micromolar range activities against DYRK1A (6.5 μM < IC50 < 1.05 μM) and submicromolar IC50 values 
against GSK3α/β (0.25 μM < IC50 < 0.97 μM). 
Undoubtedly, the most active molecules prepared in this study were series g–i of the four family of 
thiazolo[5,4-f]quinazolines (7–10). The latter showed spectacular submicromolar activities against 
DYRK1A (0.04 μM < IC50 < 0.70 μM) and GSK3α/β kinases (0.16 μM < IC50 < 0.77 μM) with a marked 
preference for the first one, respectively. The DYRK1A IC50 values obtained for 7i, 8i and 9i are situated 
in the double-digit nanomolar range (40, 47 and 50 nM, respectively) demonstrating that small-sized 
groups linked to the thiazole ring were able to induce a dramatic enhancement of the inhibitory activity 
against DYRK1A. 
Taking into account these preliminary results, defining a specific role of the aromatic substituents of 
the amine located at position 4 of the pyrimidine ring remains challenging. Nevertheless, the presence 
of substituting groups on the aromatic moiety seemed to have a positive effect on the inhibitory activity 
of the studied compounds. Without being able to establish a general rule, the presence of substituents in 
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positions 2 and 4 of the aromatic chain (series 9) has a rather beneficial effect compared to substituents 
in position 3 and 4 (series 8 and 10). 
The most active thiazoloquinazolines were less potent and specific against DYRK1A (Table 2) 
compared to harmine and leucettine L41 [25–27] but constitute a promising source of inspiration for the 
synthesis of novel bioactive molecules. Our results confirm that the thiazolo[5,4-f]quinazoline scaffold 
has a great potential in the development of potent inhibitors of DYRK1A and GSK3α/β kinases that are 
involved in many neurodegenerative diseases and cancers. Lead compounds 7i, 8i and 9i presented in 
this paper allow us to consider further structure-activity relationships for the design of more efficient 
and selective inhibitors of these targeted kinases. 
3. Experimental Section 
3.1. General Information 
All reactions were carried out under inert atmosphere of argon or nitrogen and monitored by  
thin-layer chromatography with silica gel 60 F254 pre-coated aluminum plates (0.25 mm). Visualization 
was performed with a UV light at 254 and 312 nm. Purifications were carried out on an Armen Instrument 
Spot 2 Flash System equipped with a dual UV-Vis spectrophotometer (200–600 nm), a fraction collector 
(192 tubes), a dual piston pump (1 to 250 mL/min, Pmax = 50 bar/725 psi) allowing quaternary gradients 
and an additional inlet for air purge. Samples can be injected in liquid or solid mode. Purification was 
edited and monitored on an integrated panel PC with a touch screen controlled by Armen Glider Flash 
v3.1d software [28]. Biotage SNAP flash chromatography cartridges (KP-Sil, normal phase, 10 to 340 g) 
were used for the purification process. Melting points of solid compounds were measured on a WME 
Köfler hot-stage with a precision of +/−2 °C and are uncorrected. IR spectra were recorded on a 
PerkinElmer Spectrum 100 Series FT-IR spectrometer. Liquids and solids were applied on the Single 
Reflection Attenuated Total Reflectance (ATR) Accessories. Absorption bands are given in cm−1. 
1H/19F/13C-NMR spectra were recorded on a Bruker DXP 300 spectrometer at 300, 282 and 75 MHz 
respectively. Abbreviations used for peak multiplicities are s: singlet, d: doublet, t: triplet, q: quadruplet 
and m: multiplet. Coupling constants J are in Hz and chemical shifts are given in ppm and calibrated 
with DMSO-d6 or CDCl3 (residual solvent signals). Mass spectra analysis was performed by the Mass 
Spectrometry Laboratory of the University of Rouen. Mass spectra (EI) were recorded with a Waters 
LCP 1er XR spectrometer. 
Dichloromethane was distilled from CaH2 under argon. NBS was recrystallized in water. Other 
reagents and solvents were used as provided by commercial suppliers. 
Appel salt was prepared according to literature procedure [16] by addition of chloroacetonitrile  
(1 eq) to a solution of sulfur dichloride (5 eq) in dichloromethane (50 mL). Adogen™ (3–4 drops) was 
then added and the reaction was placed in a bowl of cold water. The mixture was left for 18 h without 
stirring under CaCl2 tube protection: The dark olive green solid was removed from the wall of the flask, 
filtered off under a blanket of argon, washed abundantly with dichloromethane and dried under vacuum 
for 2–3 h (average yield: 85%): mp 172–174 °C (dec); IR (nujol) cm−1 1707, 1358 s, 1280 s, 1253, 1083, 
917, 828 s, and 605. 
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Microwave experiments were conducted at atmospheric pressure in a commercial microwave reactors 
especially designed for synthetic chemistry. Time indicated in the various protocols is the time measured 
when the mixtures reached the programmed temperature after a ramp period of 2 min. RotoSYNTH™ 
(Milestone S.r.l. Italy) is a multimode cavity with a microwave power delivery system ranging from 0 
to 1200 W. Open vessel experiments were carried out in round bottom flask (from 25 mL to 4 L) fitted 
with a reflux condenser. The temperature was monitored via a contact-less infrared pyrometer (IRT) and 
fiber-optic contact thermometer (FO). Temperature, pressure and power profiles were edited and 
monitored through the EASY-Control software provided by the manufacturer. Compounds 7a–i, 8a–i, 
9a–i and 10a–i, 16 and 17 were described in a previous patent application [29]; to help readers, 
physicochemical data of these compounds are added in the following experimental part.  
3.2. Synthesis 
3.2.1. Synthesis of Formamidine 2 and Amines 3a, 3c and 3d 
N'-(2-Cyano-4-nitrophenyl)-N,N-dimethylformamidine (2), N-(4-methoxyphenyl)-6-nitro-quinazolin-4-
amine (3a), N-(4-bromo-2-fluorophenyl)-6-nitroquinazolin-4-amine (3c) and N-(3-chloro-4-
fluorophenyl)-6-nitroquinazolin-4-amine (3d) were prepared and characterized following the general 
procedure described in [6]. 
N-(Benzo[d][1,3]dioxol-5-yl)-6-nitroquinazolin-4-amine (3b). A mixture of N'-(2-cyano-4-
nitrophenyl)-N,N-dimethylformamidine (2, 1.0 g, 4.58 mmol) and 3,4-(methylenedioxy)aniline (0.63 g, 
4.58 mmol) in acetic acid (5 mL) was heated at 118 °C under microwaves (600 W). On completion 
(followed by TLC or GC-MS), the reaction was cooled to ambient temperature. The separated solid was 
filtered and washed with diethyl ether to obtain the expected compound 3b (1.08 g, 76%) as a brown 
solid; mp > 260 °C. IR (cm−1) νmax 1581, 1512, 1490, 1321, 1245, 1222, 1188, 1031, 921, 896, 846, 807; 
1H-NMR (DMSO-d6) δ 10.3 (s, 1H, NH), 9.57 (d, 1H, J = 2.1 Hz), 8.64 (s, 1H), 8.52 (dd, 1H, J1 = 2.1 Hz, 
J2 = 9.0 Hz), 7.88 (d, 1H, J = 9.0 Hz), 7.44 (s, 1H), 7.18 (m, 1H), 6.96 (d, 1H, J = 9.0 Hz), 5.75 (s, 2H); 
13C-NMR (DMSO-d6) δ 158.6, 157.6, 152.9, 146.8, 144.2, 144.1, 132.3, 129.2, 126.2, 120.5, 116.1, 
114.1, 107.6, 105.0, 101.2; HRMS calcd for C15H11N4O4 [M+H]+ 311.0780, found 311.0794. 
3.2.2. Synthesis of Diamines 4b, 4c and 4d  
General procedure: a stirred mixture of 3b, 3c and 3d (1 mmol), ammonium formate (5 mmol) and a 
catalytic amount of 10% palladium charcoal in 20 mL of ethanol was heated at reflux (600 W) for  
30 min. The catalyst was removed by filtration through Celite and washed with ethanol. The resulting 
filtrate was evaporated under reduced pressure to give 4b, 4c and 4d. 
N4-(Benzo[d][1,3]dioxol-5-yl)quinazoline-4,6-diamine (4b). Prepared from 36 (quant. yield); brown 
solid; mp = 112–114 °C. IR (KBr) νmax/cm−1 3339, 2976, 1619, 1572, 1530, 1499, 1448, 1384, 1343, 
1255, 1190, 1095, 1045, 932, 882, 823; 1H-NMR (DMSO-d6) δ 8.20 (s, 1H), 7.51 (dd, 2H,  
J1 = 2.0 Hz, J2 = 9.0 Hz), 7.32 (d, 1H, J = 2.0 Hz), 7.23–7.18 (m, 2H), 6.91 (d, 1H, J = 9.0 Hz), 6.00 (s, 
2H); 13C-NMR (DMSO-d6) δ 163.7, 156.3, 149.9, 147.3, 146.9, 143.2, 142.1, 134.0, 128.4, 123.6, 116.6, 
115.2, 107.8, 104.6, 101.1; HRMS calcd for C15H13N4O2 [M+H]+: 281.1039, found 281.1033. 
Molecules 2014, 19 15557 
 
 
N4-(4-Bromo-2-fluorophenyl)quinazoline-4,6-diamine (4c). Prepared from 3c (yield: 93%); brown solid; 
mp = 216–218 °C. IR (cm−1) νmax 3245, 3067, 1923, 1614, 1561, 1533, 1493, 1424, 1390, 1335, 1237, 
1206, 1070, 887, 846, 825; 19F-NMR (DMSO-d6) δ −115.6; 1H-NMR (DMSO-d6) δ 8.53 (s, 1H), 7.72 
(d, 1H, J = 9.9 Hz), 7.62 (d, 1H, J = 8.7 Hz), 7.52 (m, 2H), 7.40–7.36 (m, 2H); 13C-NMR (DMSO-d6) δ 
158.8, 158.4, 155.1, 149.6, 146.6, 131.2, 130.1, 128.0, 127.9, 126.0, 124.7, 124.5, 121.7, 120.0, 119.9, 
119.8, 119.5, 115.1, 101.4; HRMS calcd for C14H11N4BrF [M+H]+: 334.0151, found 334.0158. 
N4-(3-Chloro-4-fluorophenyl)quinazoline-4,6-diamine (4d). Prepared from 3d (99% yield); brown solid; 
mp = 244–246 °C. IR (cm−1) νmax 2501, 1633, 1614, 1568, 1503, 1432, 1373, 1266, 1214, 888, 871, 794; 
19F-NMR (DMSO-d6) δ −123.9; 1H-NMR (DMSO-d6) δ 9.48 (s, 1H, NH), 8.36 (s, 1H), 8.21 (dd, 1H,  
J1 = 2.4 Hz, J2 = 6.9 Hz), 7.85–7.80 (m, 1H), 7.55 (d, 1H, J = 9.3 Hz), 7.41 (t, 1 H,  
J = 9.3 Hz); 7.30–7.24 (m, 2H); 13C-NMR (DMSO-d6) δ 155.7, 154.5, 151.3, 149.5, 147.5, 142.6, 137.4, 
137.3, 128.7, 123.8, 122.8, 121.8, 121.7, 118.8, 188.6, 116.7, 116.6, 116.3, 100.9; HRMS calcd for 
C14H11N4ClF [M+H]+: 289.0656, found 289.0663. 
3.2.3. Synthesis of Brominated Diamines 5a, 5c and 5d 
General procedure: a solution of bromine (2.9 mmol) in dichloromethane (3 mL) was added dropwise, 
under an argon atmosphere, to a solution of amines 4a, 4c and 4d (2.9 mmol) in acetic acid (34 mL). 
After 3.5 h of stirring at room temperature, the solvent was removed in vacuo. Excess acetic acid was 
co-evaporated with heptane to afford the expected compounds 5a, 5c and 5d. 
5-Bromo-N4-(4-methoxyphenyl)quinazoline-4,6-diamine (5a). Prepared from 4a (quant. Yield), beige 
solid; mp > 260 °C. IR (cm−1) νmax 3297, 3106, 3065, 2950, 2668, 1607, 1567, 1510, 1381, 1356, 1299, 
1229, 1168, 1073, 1024, 820, 802; 1H-NMR (DMSO-d6) δ 10.54 (s, 1H, NH), 8.69 (s, 1H), 7.71–7.68 
(m, 2H), 7.64 (d, 2H, J = 9.0 Hz), 7.03 (d, 2H, J = 9.0 Hz), 3.78 (s, 3H); 13C-NMR (DMSO-d6) δ 157.7, 
157.1, 147.9, 145.9, 131.7, 129.3, 125.6, 125.2, 119.4, 114.1, 113.0, 96.3, 55.5; HRMS calcd for 
C15H14N4OBr [M+H]+: 345.0351, found 345.0367. 
5-Bromo-N4-(4-bromo-2-fluorophenyl)quinazoline-4,6-diamine (5c). Prepared from 4c (quant. Yield), 
yellow solid; mp > 260 °C. IR (cm−1) νmax 3369, 3334, 3256, 1619, 1565, 1514, 1477, 1432, 1410, 1390, 
1327, 1262, 1235, 1179, 1165, 1100, 1063, 954, 928, 875, 857, 828, 815; 19F-NMR (DMSO-d6) δ −119.3; 
1H-NMR (DMSO-d6) δ 8.46 (s, 1H), 8.01 (t, 1H, J = 9.0 Hz), 7.69–7.61 (m, 2H), 7.53 (d, 1H, J = 9.0 Hz), 
7.47 (m, 1H); 13C-NMR (DMSO-d6) δ 156.3, 155.9, 152.9, 147.0, 137.3, 127.5, 126.8, 124.9, 123.5, 
118.9, 118.6, 117.5, 113.6, 94.9; HRMS calcd for C14H10N4Br2F [M+H]+: 410.9256, found 410.9243. 
5-Bromo-N4-(3-chloro-4-fluorophenyl)quinazoline-4,6-diamine (5d). Prepared from 4d (quant. Yield), 
orange solid; mp > 260 °C. IR (cm−1) νmax 3464, 3319, 3286, 3185, 2736, 1705, 1626, 1566, 1519, 1495, 
1425, 1384, 1360, 1329, 1302, 1267, 1214, 1159, 1136, 1054, 930, 872, 826; 19F-NMR (DMSO-d6)  
δ −118.8; 1H-NMR (DMSO-d6) δ 10.51 (s, 1H, NH), 8.75 (s, 1H), 8.04 (dd, 1H, J1 = 2.4 Hz, J2 = 6.9 Hz), 
7.71–7.68 (m, 2H), 7.63 (d, 1H, J = 9.0 Hz), 7.55 (t, 1H, J = 9.0 Hz); 13C-NMR (DMSO-d6) δ 157.4, 
156.8, 153.5, 148.1, 145.9, 133.8, 133.7, 132.5, 126.1, 125.6, 125.0, 124.9, 119.8, 119.5, 119.3, 117.2, 
116.9, 113.3, 95.9; HRMS calcd for C14H10N4BrClF [M+H]+: 366.9761, found 366.9770. 
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3.2.4. Synthesis of Imino-1,2,3-dithiazoles 6a, 6c and 6d 
General procedure: a suspension of the 5-bromoquinazoline 5a, 5c and 5d. (10 mmol),  
4,5-dichloro-1,2,3-dithiazolium chloride 12 (22 mmol) in dichloromethane (50 mL) was stirred at room 
temperature under an argon atmosphere. After 3 h of stirring at room temperature, pyridine (44 mmol) 
was added and the mixture was stirred again for 1 h at room temperature. Then the resulting solution 
was concentrated under reduced pressure. The obtained crude residue was purified by flash 
chromatography (DCM–EtOAc, 8:2) to afford the expected compounds 6a, 6c and 6d. 
(Z)-5-Bromo-N6-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)-N4-(4-methoxyphenyl)quinazoline-4,6-diamine 
(6a). Prepared from 5a (yield: 39%), brown solid; mp > 260 °C. IR (cm−1) νmax 3239, 1607, 1567, 1504, 
1440, 1377, 1303, 1249, 1172, 1027, 830; 1H-NMR (DMSO-d6) δ 10.93 (s, 1H, NH), 8.96 (s, 1H),  
7.95–7.85 (m, 2H), 7.66 (d, 2H, J = 9.0 Hz), 7.07 (d, 2H, J = 9.0 Hz), 3.79 (s, 3H); HRMS calcd for 
C17H12N5OS2BrCl (M + H+): 479.9355, found 479.9362. 
(Z)-5-Bromo-N4-(4-bromo-2-fluorophenyl)-N6-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)quinazoline-4,6-
diamine (6c). Prepared from 5c (yield: 30%), yellow solid; mp = 198–200 °C. IR (cm−1) νmax 3336, 3086, 
1704, 1621, 1610, 1593, 1530, 1489, 1478, 1407, 1389, 1314, 1237, 1180, 1146, 1109, 945, 921, 859, 
852, 835, 818, 810; 19F-NMR (DMSO-d6) δ −118.3; 1H-NMR (DMSO-d6) δ 9.78 (s, 1H, NH), 8.57 (s, 
1H), 7.98 (m, 1H), 7.91 (d, 1H, J = 9.0 Hz), 7.76 (d, 1H, J = 9.0 Hz), 7.70 (m, 1H), 7.49 (m, 1H); HRMS 
calcd for C16H8N5S2Br2ClF [M+H]+: 545.8260, found 585.8273. 
(Z)-5-Bromo-N4-(3-chloro-4-fluorophenyl)-N6-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)quinazoline-4,6-
diamine (6d). Prepared from 5d (yield: 39%), orange solid; mp = 218–220 °C. IR (cm−1) νmax 3353, 
2980, 1571, 1534, 1492, 1414, 1383, 1337, 1261, 1207, 1153, 1054, 960, 921, 869, 803; 19F-NMR 
(DMSO-d6) δ−118.1; 1H-NMR (DMSO-d6) δ 9.90 (s, 1H, NH), 8.62 (s, 1H), 8.08 (dd, 1H, J1 = 2.4 Hz, 
J2 = 6.9 Hz), 7.93 (d, 1H, J = 9.0 Hz), 7.77 (d, 1H, J = 9.0 Hz), 7.71–7.66 (m, 1H), 7.46 (t, 1H,  
J = 9.0 Hz); HRMS calcd for C16H8N5S2BrCl2F [M+H]+: 501.8765, found 501.8766. 
3.2.5. Synthesis of 6-Aminobenzo[d]thiazole-2,7-dicarbonitrile (16) and Its Dimethylformimidamide 
Derivative (17) 
tert-Butyl 2-cyano-4-nitrophenylcarbamate (11). To a solution of 2-amino-5-nitrobenzonitrile (1)  
(10.0 g, 61.3 mmol) in dichloromethane (100 mL) were added triethylamine (8.50 mL, 61.3 mmol),  
di-tert-butyl dicarbonate (26.8 g, 123 mmol), and 4-(dimethylamino)pyridine (7.50 g, 61.3 mmol). The 
solution was stirred for 4 h at room temperature under an argon atmosphere. The solvent was removed 
in vacuo and the crude residue was purified by flash chromatography (DCM-petroleum ether, 8:2) to 
afford the expected compound 11 (14.6 g, 91% yield) as a white solid; mp = 134–136 °C. IR (cm−1) νmax 
3412, 3072, 3012, 2982, 2935, 2229, 1735, 1617, 1582, 1543, 1508, 1473, 1455, 1420, 1372, 1350, 
1320, 1303, 1257, 1234, 1176, 1143, 1052, 1028, 923, 915, 889, 853; .1H-NMR (DMSO-d6) δ 10.04 (s, 
1H, NH), 8.63 (d, 1H, J = 2.7 Hz), 8.44–8.40 (dd, 1H, J1 = 2.7 Hz, J2 = 9.3 Hz), 7.85 (d, 1H, J = 9.3 Hz), 
1.49 (s, 9H); 13C-NMR (DMSO-d6) δ 153.1, 146.6, 142.6, 129.3, 128.8, 123.4, 115.2, 105.3, 81.2, 27.3; 
HRMS calcd for C12H12N3O4 [M+H]+: 262.0828, found 262.0831. 
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tert-Butyl 4-amino-2-cyanophenylcarbamate (12). A stirred mixture of 11 (10.0 g, 37.9 mmol), ammonium 
formate (189.5 mmol) and palladium charcoal (10%) in 300 mL of ethanol was heated at reflux under 
microwaves (600 W) for 30 min. The catalyst was removed by filtration through Celite and washed with 
ethanol. The resulting filtrate was evaporated under reduced pressure. Then, the residue was dissolved 
in EtOAc, washed with water, dried over MgSO4 and concentrated under reduced pressure to give the 
reduced compound 12 (8.4 g, 95% yield) as a pale yellow solid, mp = 126–128 °C. IR (cm−1) νmax 3476, 
3431, 3365, 3398, 2988, 2934, 2222, 1697, 1628, 1587, 1521, 1443, 1429, 1392, 1367, 1324, 1294, 
1274, 1250, 1230, 1161, 1053, 1028, 947, 902, 872, 849, 824; 1H-NMR (DMSO-d6) δ 8.82 (s, 1H, NH), 
7.02 (d, 1H, J = 8.1 Hz), 6.81 (s, 1H), 6.78 (d, 1H, J = 2.7 Hz), 5.44 (s, 2H, NH2), 1.43 (s, 9H);  
13C-NMR (DMSO-d6) δ 153.8, 146.7, 128.8, 127.9, 118.7, 117.5, 115.9, 109.8, 79.0, 28.0; HRMS calcd 
for C12H16N3O2 [M+H]+: 234.1243, found 234.1240. 
tert-Butyl 4-amino-3-bromo-2-cyanophenylcarbamate (13). A solution of bromine (25.1 mmol) in 
dichloromethane (1.3 mL) was added dropwise, under an argon atmosphere, to a solution of amine  
12 (6.5 g, 27.9 mmol) in acetic acid (325 mL). After 2.5 h of stirring at room temperature, the solvent 
was removed in vacuo. The excess of acetic acid was co-evaporated with heptane to afford the expected 
compound 13 (10.1 g, 99% yield) as a beige solid, mp = 163–165 °C. IR (cm−1) νmax 3327, 2826, 2605, 
2566, 2236, 1955, 1716, 1610, 1561, 1496, 1481, 1398, 1369, 1280, 1238, 1193, 1153, 1059, 963, 906, 
838; 1H-NMR (DMSO-d6) δ 9.05 (s, 1H, NH), 7.11 (d, 1H, J = 8.7 Hz), 7.05 (d, 1H, J = 8.7 Hz), 6.01 (s, 
2H, NH2), 1.43 (s, 9H); 13C-NMR (DMSO-d6) δ 153.6, 144.1, 131.6, 126.9, 119.6, 116.1, 112.8, 107.8, 
79.5, 28.1; HRMS calcd for C12H15N3O2Br [M+H]+: 312.0348, found 312.0354. 
tert-Butyl-3-bromo-4-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)-2-cyanophenylcarbamate (14). A 
suspension of 13 (5.0 g, 16.0 mmol), 4,5-dichloro-1,2,3-dithiazolium chloride (7.34 g, 35.2 mmol) in 
dichloromethane (100 mL) was stirred at room temperature under argon atmosphere. After 3 h of stirring, 
pyridine (5.7 mL, 70.5 mmol) was added and the mixture was stirred again for 1 h at room temperature. 
The resulting solution was concentrated under reduced pressure. The obtained crude residue was purified 
by flash chromatography (DCM-petroleum ether, 5:5) to afford the expected compound 14 (3.3 g, 46% 
yield) as an orange solid, mp = 140–150 °C (dec). IR (cm−1) νmax 3366, 2977, 2935, 2227, 1714, 1597, 
1570, 1560, 1508, 1392, 1369, 1270, 1238, 1156, 1057, 971, 859, 846, 809; 1H-NMR (DMSO-d6) δ 9.64 
(s, 1H, NH), 7.60 (d, 1H, J = 8.7 Hz), 7.55 (d, 1H, J = 8.7 Hz), 1.48 (s, 9H); 13C-NMR (DMSO-d6) δ 
163.5, 152.9, 147.4, 146.0, 140.0, 126.1, 123.6, 117.7, 115.3, 112.2, 80.4, 27.9; HRMS calcd for 
C14H13N4O2S2BrCl [M+H]+: 446.9352, found 446.9340. 
6-Amino-2-bromo-3-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)benzonitrile (15). A mixture of 
carbamate 14 (3.3 g, 7.4 mmol) and acetic acid (100 mL) was heated at 118 °C under microwaves  
(800 W) for 2 h. After cooling, the resulting solution was concentrated under reduced pressure to give 
the desired compound 15 (2.8 g, quantitative yield) as an orange solid, mp = 188–198 °C (dec.). IR 
(cm−1) νmax/3421, 3340, 3231, 2220, 1701, 1647, 1596, 1575, 1473, 1405, 1291, 1251, 1192, 1137, 973, 
869, 847, 804; 1H-NMR (DMSO-d6) δ 7.36 (d, 1H, J = 9.0 Hz), 6.91 (d, 1H, J = 9.0 Hz), 6.55 (s, 2H, 
NH2); 13C-NMR (DMSO-d6) δ 159.6, 151.7, 146.7, 137.8, 124.4, 119.0, 116.4, 115.7, 97.2; HRMS calcd 
for C9H5N4S2BrCl [M+H]+): 346.8828, found 346.8846. 
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6-Aminobenzo[d]thiazole-2,7-dicarbonitrile (16). A suspension of imine 15 (2.5 g, 7.2 mmol), copper(I) 
iodide (2.7 g, 14.4 mmol) in pyridine (50 mL) was heated at 130 °C under microwaves (400 W) for  
20 min. After cooling, the mixture was dissolved in EtOAc and washed with a sodium thiosulfate 
solution. The organic layer was dried over MgSO4, and the solvent was removed in vacuo. The crude 
residue was purified by flash chromatography (DCM–EtOAc, 9:1) to afford the expected compound 16 
(0.96 g, 67% yield) as a pale brown solid; mp = 248 °C. IR (KBr) νmax/cm−1 3433, 3350, 3250, 2225, 
1653, 1593, 1487, 1451, 1415, 1330, 1290, 1206, 1161, 1128, 821; 1H-NMR (DMSO-d6) δ 8.11 (d, 1H, 
J = 9.3 Hz), 7.31 (s, 2H, NH2), 7.10 (d, 1H, J = 9.3 Hz); 13C-NMR (DMSO-d6) δ 154.6, 143.7, 141.6, 
131.5, 130.9, 119.4, 116.9, 114.3, 83.6; HRMS calcd for C9H3N4S (M−H)−: 199.0078, found 199.0076. 
(E)-N'-(2,7-Dicyanobenzo[d]thiazol-6-yl)-N,N-dimethylformimidamide (17). A suspension of 16 (0.47 g, 
2.34 mmol) in dimethylformamide dimethyl acetal (6 mL) was heated at 70 °C under microwaves  
(600 W) during 2 min. After cooling, the brown precipitate formed was filtered, washed with Et2O and 
dried to afford the expected compound 17 (0.51 g, 86% yield) as a brown solid; mp = 185–187 °C. IR 
(cm−1) νmax 2932, 2901, 2224, 1622, 1566, 1500, 1450, 1410, 1387, 1368, 1272, 1229, 1173, 1099, 1058, 
995, 964, 928, 874, 819; 1H-NMR (DMSO-d6) δ 8.33 (d, 2H, J = 9.3 Hz), 7.62 (d, 1H, J = 9.3 Hz), 3.15 
(s, 3H), 3.07 (s, 3H); 13C-NMR (DMSO-d6) δ 157.3, 156.5, 145.9, 140.2, 133.0, 129.3, 120.3, 116.6, 
113.3, 96.4, 34.3; HRMS calcd for C12H10N5S [M+H]+: 256.0657, found 256.0644. 
3.2.6. Synthesis of Thiazolo[5,4-f]quinazoline-2-carbonitriles 7–10 
A-General Procedure from 6a–d 
A suspension of imine 6a, 6c and 6d (1 mmol), copper iodide (2 mmol) in pyridine (4 mL) was heated 
at 120 °C (600 W) for 20 min. After cooling, the mixture was dissolved in ethyl acetate, washed with 
sodium thiosulfate solution. The organic layer was dried over MgSO4, and the solvent was removed  
in vacuo. The crude residue was purified by flash chromatography (DCM–EtOAc, 8:2) to afford the 
expected compounds 7, 9 and 10. 
B-General Procedure from 17 
A mixture of (E)-N'-(2,7-dicyanobenzo[d]thiazol-6-yl)-N,N-dimethylformimidamide (17, 0.05 g, 
0.19 mmol) and the appropriate amine (0.29 mmol, 1.5 eq) in acetic acid (2 mL) was heated under 
microwaves at 118 °C (600 W). On completion (followed by TLC), the reaction was cooled to ambient 
temperature. The solvent was removed in vacuo and the crude residue was purified by flash 
chromatography to afford the expected compounds 7–10. 
9-(4-Methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile (7). Orange solid (yield: (A) 24%; 
(B) 99%); mp > 260 °C. IR IR (cm−1) νmax 3346, 2977, 2361, 2227, 1644, 1609, 1581, 1503, 1460, 1377, 
1354, 1303, 1239, 1164, 1129, 1051, 1032, 975, 829; 1H-NMR (DMSO-d6) δ 8.44 (s, 1H), 7.95 (d, 1H, 
J = 9.0 Hz), 7.70 (d, 1H, J = 9.0 Hz), 7.45 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H, J = 9.0 Hz), 3.76 (s, 3H); 
HRMS calcd for C17H12N5OS [M+H]+: 334.0763, found 334.0758. 
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9-(Benzo[d][1,3]dioxol-5-ylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile (8). Orange solid (yield: 
(B) 95%); mp > 260 °C. IR (cm−1) νmax 2894, 2226, 1734, 1706, 1645, 1609, 1581, 1555, 1499, 1471, 
1377, 1354, 1304, 1264, 1236 KBr, 1211, 1188, 1162, 1125, 1086, 1037, 972, 938, 924, 859, 829, 809; 
1H-NMR (DMSO-d6) δ 8.51 (d, 1H, J = 9.0 Hz), 8.14 (m, 1H), 7.76 (m, 1H), 6.94 (d, 2H, J = 9.0 Hz), 
6.72 (m, 1H), 6.02 (s, 2H); HRMS calcd for C17H9N5O2S [M+H]+: 348.0555, found 348.0566. 
9-(4-Bromo-2-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile (9). Brown solid (yield: (A) 
30%; (B) 70%); mp > 260 °C. IR (cm−1) νmax 3325, 3053, 2230, 1649, 1614, 1582, 1556, 1499, 1462, 
1380, 1351, 1250, 1154, 1132, 1052, 969, 904, 875, 817; 19F-NMR (DMSO-d6) δ −119.9; 1H-NMR 
(DMSO-d6) δ 8.55 (d, 1H, J = 9.0 Hz), 8.26 (d, 1H, J = 9.0 Hz), 7.78 (m, 1H), 7.55–7.52 (m, 1H),  
7.38–7.25 (m, 2H), HRMS calcd for C16H8N5SBrF [M+H]+: 399.9668, found 399.9662. 
9-(3-Chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile (10). Yellow solid (yield: 
(A) 64%; (B) 77%); mp = 252 °C. IR (cm−1) νmax 3456, 3015, 2970, 2946, 2229, 1642, 1441, 1153, 1129, 
1051, 968, 903, 817, 774, 695; 19F-NMR (DMSO-d6) δ −123.8; 1H-NMR (DMSO-d6) δ 8.43 (d, 1H,  
J = 9.0 Hz), 8.30 (s, 1H), 7.62 (m, 2H), 7.34 (m, 2H); HRMS calcd for C16H8N5SClF [M+H]+: 356.0156, 
found 356.0167. 
3.2.7. Synthesis of Carboximidamides 7a–g, 8a–g, 9a–g and 10a–g  
General procedure: A stirred mixture of carbonitrile 16 (1 mmol) and appropriate amine (1.2 mmol) 
in dry THF (7 mL) under argon was stirred overnight at room temperature. The solvent was removed  
in vacuo and the crude residue purified by flash chromatography to afford the expected carboximidamides. 
9-(4-Methoxyphenylamino)-N-(2-morpholinoethyl)thiazolo[5,4-f]quinazoline-2-carboximidamide (7a). 
Prepared from carbonitrile 7 and N-aminoethylmorpholine. Flash chromatography eluent (DCM–MeOH, 
5:5). Yellow solid (yield: 41%); mp = 130–132 °C. IR (cm−1) νmax 3362, 3175, 2920, 2852, 1643, 1567, 
1504, 1469, 1386, 1234, 1111, 1032, 964, 836; 1H-NMR (MeOD-d4) δ 8.37 (d, 1H, J = 9.0 Hz), 8.11 (s, 
1H), 7.75 (d, 1H, J = 9.0 Hz), 7.26 (d, 2H, J = 9.0 Hz), 7.01 (d, 2H, J = 9.0 Hz), 3.82 (s, 3H), 3.73 (m, 
4H), 3.48 (t, 2H, J = 7.0 Hz), 2.76 (t, 2H, J = 7.0 Hz), 2.62 (m, 4H); HRMS calcd for C23H26N7O2S 
[M+H]+: 464.1869, found 464.1874. 
9-(4-Methoxyphenylamino)-N-(2-(piperidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboximidamide 
(7b). Prepared from carbonitrile 7 and N-aminoethylpiperidine. Flash chromatography eluent  
(DCM–MeOH, 3:7). Yellow solid (yield: 43%); mp = 132–134 °C. IR (cm−1) νmax 2933, 2852, 1640, 
1613, 1572, 1507, 1376, 1349, 1302, 1283, 1237, 1155, 1124, 1035, 962, 833; 1H-NMR (MeOD-d4) δ 
8.34 (d, 1H, J = 9.0 Hz), 8.08 (s, 1H), 7.73 (d, 1H, J = 9.0 Hz), 7.23 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H,  
J = 9.0 Hz), 3.82 (s, 3H), 3.49 (t, 2H, J = 7.0 Hz), 2.73 (t, 2H, J = 7.0 Hz), 2.56 (m, 4H), 1.66 (m, 4H), 1.52 
(m, 2H); HRMS calcd for C24H28N7OS [M+H]+: 462.2076, found 462.2098. 
9-(4-Methoxyphenylamino)-N-(2-(pyrrolidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboximidamide 
(7c). Prepared from carbonitrile 7 and N-aminoethylpyrrolidine. Flash chromatography eluent  
(DCM–MeOH, 5:5). Orange solid (yield: 47%); mp = 134–136 °C. IR (cm−1) νmax 2957, 2798, 1643, 
1615, 1573, 1504, 1379, 1341, 1284, 1237, 1147, 1086, 1033, 962, 880, 833; 1H-NMR (MeOD-d4) δ 
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8.34 (d, 1H, J = 9.0 Hz), 8.08 (s, 1H), 7.73 (d, 1H, J = 9.0 Hz), 7.23 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H,  
J = 9.0 Hz), 3.82 (s, 3H), 3.49 (t, 2H, J = 7.0 Hz), 2.88 (t, 2H, J = 7.0 Hz), 2.67 (m, 4H), 1.85 (m, 4H); 
HRMS calcd for C23H26N7OS [M+H]+: 448.1920, found 448.1926. 
N-(2-(Dimethylamino)ethyl)-9-(4-methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carboximidamide 
(7d). Prepared from carbonitrile 7 and 2-dimethylaminoethylamine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Yellow solid (yield: 53%); mp = 154–156 °C. IR (cm−1) νmax 2945, 2827, 2773, 
1643, 1614, 1572, 1505, 1464, 1379, 1341, 1237, 1177, 1033, 962, 832; 1H-NMR (MeOD-d4) δ 8.30 (d, 1H, 
J = 9.0 Hz), 8.06 (s, 1H), 7.69 (d, 1H, J = 9.0 Hz), 7.22 (d, 2H, J = 9.0 Hz), 6.97 (d, 2H,  
J = 9.0 Hz), 3.81 (s, 3H), 3.43 (t, 2H, J = 7.0 Hz), 2.70 (t, 2H, J = 7.0 Hz), 2.34 (s, 6H); HRMS calcd 
for C21H24N7OS [M+H]+: 422.1763, found 422.1766. 
N-(2-(Diethylamino)ethyl)-9-(4-methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carboximidamide 
(7e). Prepared from carbonitrile 7 and diethylethylenediamine. Flash chromatography eluent  
(DCM–MeOH, 5:5). Yellow solid (yield: 50%); mp = 103–105 °C. IR (cm−1) νmax 2967, 2832, 1641, 
1614, 1572, 1507, 1378, 1341, 1285, 1237, 1178, 1086, 1034, 962, 834; 1H-NMR (MeOD-d4) δ 8.35 (d, 1H, 
J = 9.0 Hz), 8.08 (s, 1H), 7.74 (d, 1H, J = 9.0 Hz), 7.23 (d, 2H, J = 9.0 Hz), 7.01 (d, 2H,  
J = 9.0 Hz), 3.82 (s, 3H), 3.43 (t, 2H, J = 7.0 Hz), 2.86 (t, 2H, J = 7.0 Hz), 2.71 (q, 4H, J = 7.0 Hz), 1.11 
(t, 6H, J = 7.0 Hz); HRMS calcd for C23H28N7OS [M+H]+: 450.2076, found 450.2058. 
N-Benzyl-9-(4-methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carboximidamide (7f). Prepared from 
carbonitrile 7 and benzylamine. Flash chromatography eluent (DCM–EtOAc, 2:8). Yellow solid (yield: 
28%); mp = 128–130 °C. IR (cm−1) νmax 3362, 3028, 2832, 1640, 1598, 1572, 1509, 1377, 1356, 1299, 
1238, 1177, 1084, 1030, 962, 833; 1H-NMR (MeOD-d4) δ 8.34 (d, 1H, J = 9.0 Hz), 8.08 (s, 1H), 7.73 (d, 
1H, J = 9.0 Hz), 7.35 (m, 4H), 7.26 (m, 3H), 6.99 (d, 2H, J = 9.0 Hz), 4.55 (s, 2H), 3.83 (s, 3H); HRMS 
calcd for C24H21N6OS [M+H]+: 441.1498, found 441.1507. 
9-(4-Methoxyphenylamino)-N,N-dimethylthiazolo[5,4-f]quinazoline-2-carboximidamide (7g). Prepared 
from carbonitrile 7 and dimethylamine. Flash chromatography eluent (DCM–MeOH, 5:5). Pale yellow 
solid (yield: 67%); mp = 150–152 °C. IR (KBr) νmax/cm−1 3139, 2924, 1681, 1644, 1571, 1509, 1383, 
1347, 1286, 1237, 1176, 1031, 966, 834; 1H-NMR (MeOD-d4) δ 8.15 (d, 1H, J = 9.0 Hz), 7.84 (s, 1H), 
7.53 (d, 1H, J = 9.0 Hz), 7.08 (d, 2H, J = 9.0 Hz), 6.89 (d, 2H, J = 9.0 Hz), 3.77 (s, 3H), 3.13 (s, 6H); 
HRMS calcd for C19H19N6OS [M+H]+: 379.1341, found 379.1333. 
9-(Benzo[d][1,3]dioxol-5-ylamino)-N-(2-morpholinoethyl)thiazolo[5,4-f]quinazoline-2-carboximidamide 
(8a). Prepared from carbonitrile 8 and N-aminoethylmorpholine. Flash chromatography eluent  
(DCM–MeOH, 5:5). Yellow solid (yield: 41%); mp = 168–170 °C. IR (cm−1) νmax 3324, 2965, 2901, 
2861, 2812, 1641, 1616, 1587, 1503, 1468, 1382, 1353, 1304, 1271, 1232, 1180, 1148, 1114, 1067, 1036, 
969, 935, 839; 1H-NMR (MeOD-d4) δ 8.33 (d, 1H, J = 9.0 Hz), 7.96 (s, 1H), 7.71 (d, 1H, J = 9.0 Hz), 
6.87 (d, 1H, J = 9.0 Hz), 6.74 (s, 1H), 6.64 (d, 1H, J = 9.0 Hz), 5.96 (s, 2H), 3.74 (m, 4H), 3.55 (t, 2H, 
J = 7.0 Hz), 2.75 (t, 2H, J = 7.0 Hz), 2.61 (m, 4H); HRMS calcd for C23H24N7O3S [M+H]+: 478.1661, 
found 478.1649. 
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9-(Benzo[d][1,3]dioxol-5-ylamino)-N-(2-(piperidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboximi-
damide (8b). Prepared from carbonitrile 8 and N-aminoethylpiperidine. Flash chromatography eluent 
(DCM–MeOH, 3:7). Yellow solid (yield: 34%); mp = 170–172 °C. IR (cm−1) νmax 3350, 2936, 2773, 
2482, 2061, 1641, 1613, 1585, 1503, 1462, 1374, 1337, 1304, 1229, 1176, 1141, 1121, 1037, 983, 962, 
931, 855, 832; 1H-NMR (MeOD-d4) δ 8.33 (d, 1H, J = 9.0 Hz), 7.89 (s, 1H), 7.69 (d, 1H, J = 9.0 Hz), 
6.86 (d, 1H, J = 9.0 Hz), 6.75 (s, 1H), 6.63 (d, 1H, J = 9.0 Hz), 5.99 (s, 2H), 3.46 (t, 2H, J = 7.0 Hz), 
2.71 (t, 2H, J = 7.0 Hz), 2.57 (m, 4H), 1.64 (m, 4H), 1.50 (m, 2H); HRMS calcd for C24H26N7O2S 
[M+H]+: 476.1869, found 476.1883. 
9-(Benzo[d][1,3]dioxol-5-ylamino)-N-(2-(pyrrolidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (8c). Prepared from carbonitrile 8 and N-aminoethylpyrrolidine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Yellow solid (yield: 48%); mp = 172–174 °C. IR (cm−1) νmax 2906, 2803, 1643, 
1614, 1573, 1500, 1467, 1377, 1347, 1305, 1265, 1228, 1175, 1121, 1036, 966, 933, 833; 1H-NMR 
(MeOD-d4) δ 8.27 (d, 1H, J = 9.0 Hz), 7.90 (s, 1H), 7.65 (d, 1H, J = 9.0 Hz), 6.86 (d, 1H, J = 9.0 Hz), 
6.75 (s, 1H), 6.63 (d, 1H, J = 9.0 Hz), 5.97 (s, 2H), 3.46 (t, 2H, J = 7.0 Hz), 2.85 (t, 2H, J = 7.0 Hz), 2.67 
(m, 4H), 1.83 (m, 4H); HRMS calcd for C23H24N7O2S [M+H]+: 462.1712, found 462.1736. 
9-(Benzo[d][1,3]dioxol-5-ylamino)-N-(2-(dimethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (8d). Prepared from carbonitrile 8 and 2-dimethylaminoethylamine. Flash chromatography 
eluent (DCM–MeOH, 5:5). Yellow solid (yield: 10%); mp > 260 °C. IR (cm−1) νmax 3391, 2923, 2852, 
1643, 1615, 1538, 1498, 1467, 1383, 1346, 1302, 1263, 1229, 1178, 1118, 1035, 965, 933, 856, 835;  
1H-NMR (MeOD-d4) δ 8.17 (d, 1H, J = 9.0 Hz), 7.90 (s, 1H), 7.56 (d, 1H, J = 9.0 Hz), 6.86 (d, 1H,  
J = 9.0 Hz), 6.75 (s, 1H), 6.63 (d, 1H, J = 9.0 Hz), 5.91 (s, 2H), 3.43 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H,  
J = 7.0 Hz), 2.33 (s, 6H); HRMS calcd for C21H22N7O2S [M+H]+: 436.1556, found 436.1549. 
9-(Benzo[d][1,3]dioxol-5-ylamino)-N-(2-(diethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (8e). Prepared from carbonitrile 8 and diethylethylenediamine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Yellow solid (yield: 44%); mp = 144–146 °C. IR (cm−1) νmax 3333, 2970, 2920, 
2832, 1641, 1614, 1585, 1502, 1463, 1421, 1378, 1348, 1303, 1231, 1179, 1145, 1122, 1088, 1037, 965, 
933, 858, 831; 1H-NMR (MeOD-d4) δ 8.23 (d, 1H, J = 9.0 Hz), 7.89 (s, 1H), 7.62 (d, 1H, J = 9.0 Hz), 
6.86 (d, 1H, J = 9.0 Hz), 6.75 (s, 1H), 6.63 (d, 1H, J = 9.0 Hz), 5.94 (s, 2H), 3.42 (t, 2H, J = 7.0 Hz), 
2.83 (t, 2H, J = 7.0 Hz), 2.68 (q, 4H, J = 7.0 Hz), 1.10 (t, 6H, J = 7.0 Hz); HRMS calcd for C23H26N7O2S 
[M+H]+: 464.1869, found 464.1896. 
9-(Benzo[d][1,3]dioxol-5-ylamino)-N-benzylthiazolo[5,4-f]quinazoline-2-carboximidamide (8f). 
Prepared from carbonitrile 8 and benzylamine. Flash chromatography eluent (DCM–EtOAc, 2:8). 
Yellow solid (yield: 21%); mp > 260 °C. IR (cm−1) νmax 2886, 2447, 1641, 1597, 1497, 1466, 1413, 
1384, 1353, 1307, 1266, 1229, 1178, 1122, 1105, 1036, 967, 934, 861, 833; 1H-NMR (MeOD-d4) δ 8.27 
(d, 1H, J = 9.0 Hz), 7.90 (s, 1H), 7.65 (d, 1H, J = 9.0 Hz), 6.86 (m, 4H), 6.75 (m, 3H), 6.63 (d, 1H,  
J = 9.0 Hz), 5.97 (s, 2H), 4.58 (s, 2H); HRMS calcd for C24H19N6O2S [M+H]+: 455.1290, found 455.1287. 
9-(4-Bromo-2-fluorophenylamino)-N-(2-morpholinoethyl)thiazolo[5,4-f]quinazoline-2-carboximid-amide 
(9a). Prepared from carbonitrile 9 and N-aminoethylmorpholine. Flash chromatography eluent  
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(DCM–MeOH, 5:5). Yellow solid (yield: 85%); mp = 190–192 °C. IR (cm−1) νmax 3374, 2975, 2361, 
1645, 1585, 1381, 1265, 1227, 1090, 1053, 973, 916, 882, 825; 19F-NMR (DMSO-d6) δ −120.0;  
1H-NMR (DMSO-d6) δ 8.52 (d, 1H, J = 9.0 Hz), 8.26 (m, 1H), 7.78 (m, 1H), 7.57 (m, 1H), 7.36 (m, 
1H), 7.16 (m, 1H), 3.66 (t, 4H, J = 4.5 Hz), 3.48–3.42 (m, 2H), 2.69 (t, 2H, J = 6.0 Hz), 2.61 (m, 4H); 
HRMS calcd for C22H22N7OSBrF [M+H]+: 530.0774, found 530.0782. 
9-(4-Bromo-2-fluorophenylamino)-N-(2-(piperidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (9b). Prepared from carbonitrile 9 and N-aminoethylpiperidine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Yellow solid (yield: 72%); mp = 142–144 °C. IR (cm−1) νmax 3340, 2975, 2930, 
2361, 1615, 1561, 1476, 1380, 1348, 1262, 1197, 1153, 1114, 1052, 881, 821; 19F-NMR (CDCl3) δ −123.8; 
1H-NMR (CDCl3) δ 8.25 (d, 1H, J = 9.0 Hz), 8.09 (s, 1H), 7.55 (d, 1H, J = 9.0 Hz), 7.50–7.45 (m, 1H), 
7.29 (t, 1H, J = 9.0 Hz), 7.12–7.06 (m, 1H), 3.54 (m, 2H), 2.67 (t, 2H, J = 5.7 Hz), 2.54 (m, 4H),  
1.66–1.60 (m, 4H), 1.49 (m, 2H); HRMS calcd for C23H24N7SBrF [M+H]+: 528.0981, found 528.0986. 
9-(4-Bromo-2-fluorophenylamino)-N-(2-(pyrrolidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (9c). Prepared from carbonitrile 9 and N-aminoethylpyrrolidine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Orange solid (yield: 68%); mp = 138–140 °C. IR (cm−1) νmax 2968, 2361, 1563, 
1476, 1380, 1262, 1223, 1067, 965, 880, 822; 19F-NMR (MeOD-d4) δ −123.6; 1H-NMR (MeOD-d4) δ 
8.29 (d, 1H, J = 9.0 Hz), 7.89 (s, 1H), 7.63 (d, 1H, J = 9.0 Hz), 7.35–7.29 (m, 2H), 7.09 (t, 1H, J = 9.0 Hz), 
3.46 (t, 2H, J = 6.6 Hz), 2.87 (t, 2H, J = 6.6 Hz), 2.69 (m, 4H), 1.89 (m, 4H); HRMS calcd for 
C22H22N7SBrF [M+H]+: 514.0825, found 514.0825. 
9-(4-Bromo-2-fluorophenylamino)-N-(2-(dimethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (9d). Prepared from carbonitrile 9 and 2-dimethylaminoethylamine. Flash chromatography 
eluent (DCM–MeOH, 5:5). Orange solid (yield: 64%); mp = 128–130 °C. IR (cm−1) νmax 3274, 3058, 
2940, 2861, 2822, 2773, 1618, 1560, 1478, 1380, 1341, 1262, 1197, 1155, 1112, 1038, 965, 881, 823; 
19F-NMR (MeOD-d4 ) δ −122.3; 1H-NMR (MeOD-d4) δ 8.33 (d, 1H, J = 9.0 Hz), 7.92 (s, 1H), 7.68  
(d, 1H, J = 9.0 Hz), 7.41–7.36 (m, 2H), 7.15 (t, 1H, J = 9.0 Hz), 3.46 (t, 2H, J = 6.6 Hz), 2.76 (t, 2H,  
J = 6.6 Hz), 2.37 (s, 6H); HRMS calcd for C20H20N7SBrF [M+H]+: 488.0668, found 488.0688. 
9-(4-Bromo-2-fluorophenylamino)-N-(2-(diethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (9e). Prepared from carbonitrile 9 and diethylethylenediamine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Orange solid (yield: 86%); mp = 88–100 °C. IR (cm−1) νmax 2965, 2360, 1793, 
1619, 1520, 1477, 1378, 1265, 1198, 1067, 966, 880, 822; 19F-NMR (MeOD-d4) δ −122.1; 1H-NMR 
(MeOD-d4) δ 8.30 (d, 1H, J = 9.0 Hz), 7.93 (s, 1H), 7.66 (d, 1H, J = 9.0 Hz), 7.38–7.33 (m, 2H), 7.13 
(t, 1H, J = 9.0 Hz), 3.58 (t, 2H, J = 6.6 Hz), 2.82 (t, 2H, J = 6.6 Hz), 2.68 (m, 4H), 1.09 (m, 6H); HRMS 
calcd for C22H24N7SBrF [M+H]+: 516.0981, found 516.0988. 
N-Benzyl-9-(4-bromo-2-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carboximidamide (9f). Prepared 
from carbonitrile 9 and benzylamine. Flash chromatography eluent (DCM–EtOAc, 2:8). Yellow solid 
(yield: 68%); mp = 130–132 °C. IR (cm−1) νmax 2964, 2903, 2360, 1815, 1614, 1477, 1379, 1262, 1153, 
1113, 1069, 966, 880, 821; 19F-NMR (MeOD-d4) δ −122.2; 1H-NMR (MeOD-d4) δ 8.35 (d, 1H,  
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J = 9.0 Hz), 7.92 (s, 1H), 7.69 (d, 1H, J = 9.0 Hz), 7.43 (m, 3H), 7.39–7.30 (m, 3H), 7.25 (m, 1H), 7.15 
(t, 1H, J = 9.0 Hz), 4.53 (s, 2H); HRMS calcd for C23H17N6SBrF [M+H]+: 507.0403, found 507.0412. 
9-(4-Bromo-2-fluorophenylamino)-N-(2-(dimethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (9g). Prepared from carbonitrile 9 and dimethylamine. Flash chromatography eluent  
(DCM–MeOH, 5:5). Orange solid (yield: 40%); mp = 222–224 °C. IR (cm−1) νmax 3270, 3154, 3061, 
2923, 1634, 1584, 1519, 1492, 1410, 1346, 1291, 1226, 1201, 1152, 1116, 1049, 964, 881, 863, 831; 
19F-NMR (MeOD-d4) δ −121.6; 1H-NMR (MeOD-d4) δ 8.18 (d, 1H, J = 9.0 Hz), 7.87 (s, 1H), 7.53 (d, 
1H, J = 9.0 Hz), 7.28–7.19 (m, 2H), 7.12 (t, 1H, J = 9.0 Hz), 3.11 (s, 6H); HRMS calcd for C18H15N6SBrF 
[M+H]+: 445.0246, found 445.0264. 
9-(3-Chloro-4-fluorophenylamino)-N-(2-morpholinoethyl)thiazolo[5,4-f]quinazoline-2-carboximid-
amide (10a). Prepared from carbonitrile 10 and N-aminoethylmorpholine. Flash chromatography eluent 
(DCM–MeOH, 5:5). Yellow solid (yield: 71%); mp = 158–160 °C. IR (cm−1) νmax 2956, 2816, 1797, 
1614, 1561, 1485, 1256, 1199, 1113, 1069, 966, 916, 816; 19F-NMR (DMSO-d6) δ −119.1; 1H-NMR 
(DMSO-d6) δ 8.87 (s, 1H, NH), 8.43 (d, 1H, J = 7.2 Hz), 8.03 (m, 1H), 7.90 (m, 1H), 7.52 (m, 1H), 7.39 (m, 
1H), 7.18 (m, 1H), 3.78–3.75 (m, 4H), 3.52 (m, 2H), 2.76–2.72 (m, 2H), 2.60 (m, 4H); HRMS calcd for 
C22H22N7OSClF [M+H]+: 486.1279, found 486.1292. 
9-(3-Chloro-4-fluorophenylamino)-N-(2-(piperidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (10b). Prepared from carbonitrile 10 and N-aminoethylpiperidine. Flash chromatography 
eluent (DCM–MeOH, 3:7). Orange solid (yield: 82%); mp = 146–148 °C. IR (cm−1) νmax 2928, 2361, 
1572, 1483, 1380, 1255, 1201, 1121, 1086, 1051, 964, 879, 818; 19F-NMR (CDCl3) δ ‒123.8; 1H-NMR 
(CDCl3) δ 8.62 (s, 1H), 8.35 (d, 1H, J = 9.0 Hz), 7.90 (d, 1H, J = 9.0 Hz), 7.70 (m, 1H), 7.32 (m, 1H), 
7.12 (t, 1H, J = 9.0 Hz), 3.50 (m, 2H), 2.63 (t, 2H, J = 5.7 Hz), 2.49 (m, 4H), 1.63–1.58 (m, 4H), 1.48 (m, 
2H); HRMS calcd for C23H24N7SClF [M + H]+: 484.1486, found 484.1501. 
9-(3-Chloro-4-fluorophenylamino)-N-(2-(pyrrolidin-1-yl)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (10c). Prepared from carbonitrile 10 and N-aminoethylpyrrolidine. Flash chromatography 
eluent (DCM–MeOH, 5:5). Orange solid (yield: 34%); mp = 166–168 °C. IR (cm−1) νmax 3381, 3146, 
2965, 2803, 1641, 1617, 1562, 1486, 1383, 1341, 1253, 1200, 1127, 1050, 965, 876, 816; 19F-NMR 
(MeOD-d4) δ −125.6; 1H-NMR (MeOD-d4) δ 8.22 (d, 1H, J = 9.0 Hz), 7.95 (s, 1H), 7.59 (d, 1H, J = 9.0 Hz), 
7.31 (m, 1H), 7.18 (t, 1H, J = 9.0 Hz), 7.15–7.12 (m, 1H), 3.45 (m, 2H), 2.85 (m, 2H), 2.67 (m, 4H), 
1.83 (m, 4H); HRMS calcd for C22H22N7SClF [M+H]+: 470.1330, found 470.1340. 
9-(3-Chloro-4-fluorophenylamino)-N-(2-(dimethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (10d). Prepared from carbonitrile 10 and 2-dimethylaminoethylamine. Flash chromatography 
eluent (DCM–MeOH, 5:5). Pale yellow solid (yield: 50%); mp = 172–174 °C. IR (cm−1) νmax 3224, 3038, 
2950, 2861, 2824, 2773, 1618, 1560, 1488, 1386, 1323, 1254, 1195, 1127, 1086, 1052, 967, 816;  
19F-NMR (MeOD-d4) δ −125.5; 1H-NMR (MeOD-d4) δ 8.34 (d, 1H, J = 9.0 Hz), 7.93 (s, 1H), 7.67 (d, 
1H, J = 9.0 Hz), 7.29 (m, 1H), 7.18 (t, 1H, J = 9.0 Hz), 7.10–7.06 (m, 1H), 3.64 (t, 2H, J = 6.0 Hz), 3.27 
(t, 2H, J = 6.0 Hz), 2.80 (s, 6H); HRMS calcd for C20H20N7SClF [M+H]+: 444.1173, found 444.1155. 
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9-(3-Chloro-4-fluorophenylamino)-N-(2-(diethylamino)ethyl)thiazolo[5,4-f]quinazoline-2-carboxi-
midamide (10e). Prepared from carbonitrile 10 and diethylethylenediamine. Flash chromatography 
eluent (DCM–MeOH, 5:5). Orange solid (yield: 50%); mp = 140–142 °C. IR (cm−1) νmax 3295, 2969, 
2812, 1671, 1618, 1560, 1489, 1386, 1346, 1254, 1196, 1127, 1052, 966, 817; 19F-NMR (MeOD-d4) δ 
−125.3; 1H-NMR (MeOD-d4) δ 8.29 (d, 1H, J = 9.0 Hz), 7.94 (s, 1H), 7.63 (d, 1H, J = 9.0 Hz),  
7.29–7.20 (m, 2H), 7.09 (m, 1H), 3.60–3.56 (m, 2H), 2.90–2.83 (m, 2H), 2.77–2.74 (m, 4H), 1.17–1.06 
(m, 6H); HRMS calcd for C22H24N7SClF [M+H]+: 472.1486, found 472.1502. 
N-Benzyl-9-(3-chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carboximidamide (10f). Prepared 
from carbonitrile 10 and benzylamine. Flash chromatography eluent (DCM–EtOAc, 2:8). Yellow solid 
(yield: 69%); mp = 230–232 °C. IR (cm−1) νmax 3057, 1725, 1639, 1490, 1377, 1341, 1252, 1202, 1151, 
1121, 1086, 1050, 965, 818; 19F-NMR (282 MHz, MeOD-d4) δ −125.3; 1H-NMR (300 MHz, MeOD-d4) 
δ 8.29 (d, 1H, J = 9.0 Hz), 7.94 (s, 1H), 7.63 (d, 1H, J = 9.0 Hz), 7.43 (m, 2H), 7.35–7.17 (m, 5H), 7.10 
(m, 1H), 4.53 (s, 2H); HRMS calcd for C23H17N6SClF [M+H]+: 463.0908, found 463.0916. 
9-(3-Chloro-4-fluorophenylamino)-N,N-dimethylthiazolo[5,4-f]quinazoline-2-carboximidamide (10g). 
Prepared from carbonitrile 10 and dimethylamine. Flash chromatography eluent (DCM–MeOH, 5:5). 
Yellow solid (yield: 43%); mp > 260 °C. IR (KBr) νmax/cm−1 3411, 3051, 1663, 1623, 1559, 1488, 1383, 
1254, 1202, 1150, 1051, 966, 819; 19F-NMR (MeOD-d4) δ −125.9; 1H-NMR (MeOD-d4) δ 8.45 (d, 1H, 
J = 9.0 Hz), 7.98 (s, 1H), 7.75 (d, 1H, J = 9.0 Hz), 7.30–7.21 (m, 2H), 7.12 (t, 1H, J = 9.0 Hz), 3.39 (s, 
6H); HRMS calcd for C18H15N6SClF [M+H]+: 401.0751, found 401.0742. 
3.2.8. Synthesis of Amides 7h–10h  
General procedure: a stirred mixture of carbonitriles 7–10 (0.13 mmol) and NaOH (2.5 N sol., 50 μL) 
in butanol (2.5 mL) was heated under microwaves at 117 °C (600 W) for 30 min. The solvent was 
removed in vacuo and the crude residue purified by flash chromatography (DCM–EtOAc, 5:5) to afford 
amides 7h–10h. 
9-(4-Methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carboxamide (7h). Orange solid (yield: 98%); 
mp = 213 °C. IR (cm−1) νmax 3409, 1691, 1638, 1600, 1572, 1509, 1431, 1380, 1349, 1325, 1301, 1237, 
1177, 1123, 1085, 1032, 964, 835, 814; 1H-NMR (DMSO-d6) δ 8.37 (s, 1H), 8.24 (d, 1H, J = 9.0 Hz), 
8.06 (s, 1H), 7.92 (s, 1H), 7.61 (d, 1H, J = 9.0 Hz), 7.31 (d, 2H, J = 9.0 Hz), 6.89 (d, 2H, J = 9.0 Hz), 
3.74 (s, 3H); HRMS calcd for C17H14N5O2S [M+H]+: 352.0868, found 352.0879. 
9-(Benzo[d][1,3]dioxol-5-ylamino)thiazolo[5,4-f]quinazoline-2-carboxamide (8h). Yellow solid (yield: 
31%); mp > 260 °C. IR (KBr) νmax/cm−1 3291, 2915, 1648, 1576, 1532, 1497, 1476, 1376, 1351, 1323, 
1272, 1191, 1104, 1035, 965, 923, 830, 815; 1H-NMR (DMSO-d6) δ 8.05–7.98 (m, 2H), 7.49 (d, 1H,  
J = 2 Hz), 7.37–7.31 (m, 1H), 6.96 (dd, 1H, J1 = 2 Hz, J2 = 9 Hz), 6.73 (dd, 1H, J1 = 2 Hz, J2 = 9 Hz), 
5.88 (s, 2H); HRMS calcd for C17H12N5O3S [M+H]+: 366.0661, found 366.0658. 
9-(4-Bromo-2-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carboxamide (9h). Yellow solid (yield: 
71%); mp > 260 °C. IR (KBr) νmax/cm−1 1682, 1645, 1615, 1575, 1557, 1486, 1347, 1254, 1200, 1158, 
1118, 1074, 993, 967, 941, 865, 819; 19F-NMR (DMSO-d6) δ −120.5; 1H-NMR (DMSO-d6) δ 8.47 (s, 
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1H), 8.41 (d, 1H, J = 9.0 Hz), 8.39 (s, 1H), 8.14 (s, 1H), 8.03 (d, 1H, J = 9.0 Hz), 7.53 (m, 1H), 7.36 (m, 
1H), 7.21 (t, 1H, J = 9.0 Hz); HRMS calcd for C16H10N5OSBrF [M+H]+: 417.9769, found 417.9769. 
9-(3-Chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carboxamide (10h). Orange solid 
(yield: 98%); mp > 260 °C. IR (KBr) νmax/cm−1 3453, 1684, 1624, 1601, 1576, 1534, 1506, 1487, 1376, 
1348, 1282, 1260, 1209, 1124, 1085, 1057, 993, 969, 825, 810; 19F-NMR (DMSO-d6) δ −129.1;  
1H-NMR (DMSO-d6) δ 8.26–8.21 (m, 2H), 8.12 (d, 1H, J = 9.0 Hz), 8.02–7.99 (m, 1H), 7.80 (s, 1H), 
7.53 (d, 1H, J = 9.0 Hz), 7.47 (m, 1H), 7.18 (t, 1H, J = 9.0 Hz); HRMS calcd for C16H10N5OSClF 
[M+H]+: 374.0279, found 374.0280. 
3.2.9. Synthesis of Methylimidates 7i–10i 
General procedure: a stirred mixture of carbonitriles 7–10 (0.13 mmol) and NaOCH3 (0.5 M sol. in 
MeOH, 130 μL) in methanol (4 mL) was heated under microwaves at 65 °C (600 W) for 30 min. The 
solvent was removed in vacuo and the crude residue purified by flash chromatography (DCM–EtOAc) 
to afford imidates 7i–10i. 
Methyl 9-(4-methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carbimidate (7i). Purified by flash 
chromatography (DCM–EtOAc, 5:5) as orange solid (yield: 82%); mp = 240–242 °C. IR (cm−1); νmax 
2833, 2354, 1644, 1614, 1567, 1504, 1439, 1397, 1373, 1349, 1325, 1286, 1240, 1215, 1181, 1155, 
1104, 1069, 1033, 965, 935, 859, 832, 814; 1H-NMR (MeOD-d4) δ 8.09 (d, 1H, J = 9.0 Hz), 7.93 (s, 
1H), 7.50 (d, 1H, J = 9.0 Hz), 7.14 (d, 2H, J = 9.0 Hz), 6.82 (d, 2H, J = 9.0 Hz), 3.98 (s, 3H), 3.74 (s, 
3H); HRMS calcd for C18H16N5O2S [M+H]+: 366.1025, found 366.1034. 
Methyl 9-(benzo[d][1,3]dioxol-5-ylamino)thiazolo[5,4-f]quinazoline-2-carbimidate (8i). Purified by 
flash chromatography (DCM–EtOAc, 5:5) as yellow solid (yield: 92%); mp = 230–232 °C. IR (cm−1) 
νmax/3287, 2902, 1648, 1617, 1575, 1528, 1499, 1483, 1452, 1432, 1385, 1322, 1272, 1196, 1125, 1043, 
936, 885, 834, 817; 1H-NMR (DMSO-d6) δ 8.36 (d, 1H, J = 9 Hz), 7.96 (s, 1H), 7.71 (d, 1H, J = 9 Hz), 
6.87 (d, 1H, J = 8 Hz), 6.74 (m, 1H), 6.63 (d, 1H, J = 8 Hz), 5.96 (s, 2H), 4.05 (s, 3H); HRMS calcd for 
C18H14N5O3S [M+H]+: 380.0817, found 380.0805. 
Methyl 9-(4-bromo-2-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carbimidate (9i). Purified by 
flash chromatography eluent (DCM–EtOAc, 2:8) as pale yellow solid (yield: 94%); mp > 260 °C. IR 
(cm−1) νmax 2950, 1638, 1617, 1595, 1555, 1507, 1479, 1434, 1398, 1352, 1325, 1288, 1224, 1197, 1159, 
1115, 1070, 988, 965, 942, 882, 818; 19F-NMR (DMSO-d6) δ −119.8; 1H-NMR (DMSO-d6) δ 8.46 (d, 1H, 
J = 9.0 Hz), 8.02 (s, 1H), 7.69 (d, 1H, J = 9.0 Hz), 7.53 (m, 1H), 7.35 (m, 1H), 7.20 (t, 1H, J = 9.0 Hz), 
3.94 (s, 3H); HRMS calcd for C17H12N5OSBrF [M+H]+: 431.9930, found 431.9937. 
Methyl 9-(3-chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carbimidate (10i). Purified by 
flash chromatography (DCM–EtOAc, 5:5) as orange solid (yield: 98%); mp = 210–212 °C. IR (KBr) 
νmax/cm−1 1642, 1559, 1479, 1352, 1260, 1201, 1156, 1073, 942, 817; 19F-NMR (DMSO-d6) δ −126.9; 
1H-NMR (DMSO-d6) δ 8.29 (d, 1H, J = 9.0 Hz), 8.18 (s, 1H), 7.73 (m, 1H), 7.61 (d, 1H, J = 9.0 Hz), 
7.30 (m, 1H), 7.27 (t, 1H, J = 9.0 Hz), 3.95 (s, 3H); HRMS calcd for C17H12N5OSClF [M+H]+: 388.0435, 
found 388.0447. 
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3.3. In Vitro Kinase Preparation and Assays [19] 
3.3.1. Buffers 
Buffer A: MgCl2 (10 mM), 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
(EGTA), 1 mM dithiothreitol (DTT), 25 mM Tris-HCl pH 7.5, 50 μg heparin/mL. 
Buffer B: β-Glycerophosphate (60 mM), 30 mM p-nitrophenylphosphate, 25 mM  
3-(N-morpholino)propanesulfonic acid (Mops) (pH 7.2), 5 mM EGTA, 15 mM MgCl2, 1 mM DTT,  
0.1 mM sodium vanadate. 
3.3.2. Kinase Preparations and Assays 
Kinase activities were assayed in triplicates in buffer A or B, for 30 min. at 30 °C, at a final adenosine 
triphosphate (ATP) concentration of 15 μM. Blank values were subtracted and activities expressed in % 
of the maximal activity, i.e., in the absence of inhibitors. Controls were performed with appropriate 
dilutions of dimethylsulfoxide (DMSO). IC50 values were calculated from dose-response curves 
established by Sigma-Plots. The GSK-3, CK1, DYRK1A and CLK1 peptide substrates were obtained 
from Proteogenix (Oberhausbergen, France). 
CDK5/p25. (Human, recombinant) was prepared as previously described [20,21]. Its kinase activity 
was assayed in buffer A, with 1 mg of histone H1/mL, in the presence of 15 μM [γ-33P] ATP  
(3000 Ci/mmol; 10 mCi/mL) in a final volume of 30 μL. After 30 min incubation at 30 °C, 25 μL aliquots 
of supernatant were spotted onto sheets of Whatman P81 phosphocellulose paper, and 20 s later, the 
filters were washed eight times (for at least 5 min each time) in a solution of 10 mL phosphoric acid/L 
of water. The wet filters were counted in the presence of 1 mL ACS (Amersham) scintillation fluid.  
GSK-3α/β. (Porcine brain, native) was assayed as described for CDK5/p25, but in buffer A and  
using a GSK-3 specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQpSEDEEE) (pS stands for 
phosphorylated serine) [22]. 
CK1δ/ε. (Porcine brain, native) was assayed as described for CDK5/p25, but using the CK1-specific 
peptide substrate RRKHAAIGpSAYSITA [23]. 
DYRK1A. (Rat, recombinant, expressed in E. coli as a glutathione transferase (GST) fusion protein) 
was purified by affinity chromatography on glutathione-agarose and assayed, as described for 
CDK5/p25 using Woodtide (KKISGRLSPIMTEQ) (1.5 µg/assay) as a substrate.  
4. Conclusions 
The convenient synthesis of a forty molecule library of novel 6,6,5-tricyclic thiazolo[5,4-f]-quinazolines 
was realized under microwave irradiation associating Dimroth rearrangement for construction the 
pyrimidine part and 4,5-dichloro-1,2,3,-dithiazolium chloride (Appel salt) chemistry for introducing the 
thiazole ring to its quinazoline partner. Our work allowed to prepare in an efficient and reproducible 
multistep synthesis a novel 6-aminobenzo[d]thiazole-2,7-dicarbonitrile (16) which can be considered as 
a very powerful molecular platform for the synthesis of various bioactive derivatives. On chemical and 
practical aspects this article is a further example illustrating how microwave heating can be a very 
powerful tool for medicinal chemistry.  
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The inhibitory potency of the final products against a panel of four kinases was evaluated. In view of 
the results of this preliminary study, we consider that the thiazolo[5,4-f]quinazoline derivatives (series 
7–10) constitute a promising source of inspiration for the synthesis of novel bioactive molecules. Novel 
synthetic transformations will be explored and factors governing the dual activity of the compounds 
toward DYRK1A and GSK3 will be further investigated.  
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